AEG-1 promoter-mediated imaging of prostate cancer

Akrita Bhatnagar, Yuchuan Wang, Ronnie Mease, Matthew Gabrielson, Polina Sysa, Il Minn, Gilbert Green, Brian Simmons, Kathleen L Gabrielson, Siddik Sarkar, Paul B. Fisher, Martin Gilbert Pomper

Research output: Contribution to journalArticle

Abstract

We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)5772-5781
Number of pages10
JournalCancer Research
Volume74
Issue number20
DOIs
StatePublished - Oct 15 2014

Fingerprint

Prostatic Neoplasms
Bone and Bones
Sodium Fluoride
Fluorodeoxyglucose F18
Single-Photon Emission-Computed Tomography
Reporter Genes
Nanoparticles
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

AEG-1 promoter-mediated imaging of prostate cancer. / Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie; Gabrielson, Matthew; Sysa, Polina; Minn, Il; Green, Gilbert; Simmons, Brian; Gabrielson, Kathleen L; Sarkar, Siddik; Fisher, Paul B.; Pomper, Martin Gilbert.

In: Cancer Research, Vol. 74, No. 20, 15.10.2014, p. 5772-5781.

Research output: Contribution to journalArticle

Bhatnagar, A, Wang, Y, Mease, R, Gabrielson, M, Sysa, P, Minn, I, Green, G, Simmons, B, Gabrielson, KL, Sarkar, S, Fisher, PB & Pomper, MG 2014, 'AEG-1 promoter-mediated imaging of prostate cancer', Cancer Research, vol. 74, no. 20, pp. 5772-5781. https://doi.org/10.1158/0008-5472.CAN-14-0018
Bhatnagar, Akrita ; Wang, Yuchuan ; Mease, Ronnie ; Gabrielson, Matthew ; Sysa, Polina ; Minn, Il ; Green, Gilbert ; Simmons, Brian ; Gabrielson, Kathleen L ; Sarkar, Siddik ; Fisher, Paul B. ; Pomper, Martin Gilbert. / AEG-1 promoter-mediated imaging of prostate cancer. In: Cancer Research. 2014 ; Vol. 74, No. 20. pp. 5772-5781.
@article{ad602be797c24b948ec71cf1b6705845,
title = "AEG-1 promoter-mediated imaging of prostate cancer",
abstract = "We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.",
author = "Akrita Bhatnagar and Yuchuan Wang and Ronnie Mease and Matthew Gabrielson and Polina Sysa and Il Minn and Gilbert Green and Brian Simmons and Gabrielson, {Kathleen L} and Siddik Sarkar and Fisher, {Paul B.} and Pomper, {Martin Gilbert}",
year = "2014",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-14-0018",
language = "English (US)",
volume = "74",
pages = "5772--5781",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - AEG-1 promoter-mediated imaging of prostate cancer

AU - Bhatnagar, Akrita

AU - Wang, Yuchuan

AU - Mease, Ronnie

AU - Gabrielson, Matthew

AU - Sysa, Polina

AU - Minn, Il

AU - Green, Gilbert

AU - Simmons, Brian

AU - Gabrielson, Kathleen L

AU - Sarkar, Siddik

AU - Fisher, Paul B.

AU - Pomper, Martin Gilbert

PY - 2014/10/15

Y1 - 2014/10/15

N2 - We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.

AB - We describe a new imaging method for detecting prostate cancer, whether localized or disseminated and metastatic to soft tissues and bone. The method relies on the use of imaging reporter genes under the control of the promoter of AEG-1 (MTDH), which is selectively active only in malignant cells. Through a systemic, nanoparticle-based delivery of the imaging construct, lesions can be identified through bioluminescence imaging and single-photon emission computed tomography in the PC3-ML murine model of prostate cancer at high sensitivity. This approach is applicable for the detection of prostate cancer metastases, including bone lesions for which there is no current reliable agent for noninvasive clinical imaging. Furthermore, the approach compares favorably with accepted and emerging clinical standards, including PET with [18F]fluorodeoxyglucose and [18F]sodium fluoride. Our results offer a preclinical proof of concept that rationalizes clinical evaluation in patients with advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908146948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908146948&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0018

DO - 10.1158/0008-5472.CAN-14-0018

M3 - Article

C2 - 25145668

AN - SCOPUS:84908146948

VL - 74

SP - 5772

EP - 5781

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -